Articles for author: Ron Finklestien

January 8, 2024

Ron Finklestien

Investor Alert: U.S. Crude Oil Drops 4% as Saudi Price Cut Sparks Global Demand Concerns Investor Alert: U.S. Crude Oil Drops 4% as Saudi Price Cut Sparks Global Demand Concerns

SlavkoSereda/iStock via Getty Images Monday’s trading delivered a rude awakening for energy investors as U.S. oil futures experienced their most substantial single-day decline since November. The culprit? Saudi Arabia’s decision to slash its crude selling prices, reigniting fears of an over-supplied market combined with weakening demand. Energy (NYSEARCA:XLE) was the sole S&P sector to conclude the day in the red, finishing -1.2%. Saudi Aramco declared a reduction in its official selling price for crude to all regions starting February, including a significant cut for its flagship Arab light, surpassing local benchmarks by up to $2 per barrel. Front-month Nymex crude

January 8, 2024

Ron Finklestien

CES Concept Cars and the Growing Need For More Advanced Semiconductors CES Concept Cars and the Growing Need For More Advanced Semiconductors

Year after year, the world’s biggest technology brands gather to showcase their new products and innovative technologies at the Consumer Electronics Show (CES). Products highlighted span across TVs, cars, wearables, smart home tech, and more. CES has evolved over recent years and has become a major conference for news in the automotive industry as the car is becoming the most sophisticated technology platform. “The automotive business is going through one of the largest and most significant transformations faster than it ever has,” said Dipti Vachani, Arm’s GM & SVP of Automotive. From a technologist’s perspective, this all translates into a

January 8, 2024

Ron Finklestien

Top 3 Dividend Growers for Savvy Income Investors Top 3 Dividend Growers for Savvy Income Investors

Dividends – the sweet siren song of the investment world. Like the soothing lullaby of a summer breeze, dividends offer investors not only a passive income stream but a cushion against the capricious vagaries of the market. Embracing dividends can be akin to finding shelter during a financial storm, enabling investors to reap the bounty through reinvestment. Diving deeper into the lair of corporate finance, the ability of a company to consistently elevate its dividend payouts is a concrete testament to its financial fortitude, a sign of a stable and robust footing. Furthermore, such dividend hikes serve as a reassuring

January 8, 2024

Ron Finklestien

What’s The Buzz With Elevation Oncology Stock?

Elevation Oncology, Inc. ELEV shares soared on Monday, following the company’s announcement of program updates and upcoming 2024 milestones on Friday. The gritty details Elevation Oncology aims to deliver an update from its ongoing Phase 1 trial of EO-3021 in mid-2024, with additional data expected in the first half of 2025. Additionally, the company plans to expand its clinical development program to evaluate EO-3021 in combination and intends to provide more details on the program in the first half of 2024. “Our vision is to leverage our ADC and oncology drug development expertise to deliver innovative, selective cancer therapies to

January 8, 2024

Ron Finklestien

News Update: Mining Stocks and Earnings Reports Positive Movement in Mining Stocks and Earnings Reports

Upgrade for Freeport-McMoRan Freeport-McMoRan Inc. (NYSE: FCX) received an upgrade from Market Perform to Outperform, with its price target raised from $41 to $48.50 by an analyst at Bernstein. Downgrade for Barrick Gold Barrick Gold Corporation (NYSE: GOLD) faced a downgrade from Outperform to Market Perform by an analyst at Bernstein, with no price target given. Commercial Metals Reports Earnings Commercial Metals (NYSE: CMC) reported earnings of $1.49 per diluted share, marking a year-over-year decline of 33%. The net sales amounted to $2 billion, reflecting a year-over-year decline of 9%, with free cash flow of $194.1 million. President and Chief

January 8, 2024

Ron Finklestien

Alcoa’s Decision to Curtail Production at Kwinana Alumina Plant in Australia Alcoa’s Decision to Curtail Production at Kwinana Alumina Plant in Australia

Jeff Swensen/Getty Images News Alcoa, a prominent player listed on the New York Stock Exchange under the ticker symbol NYSE:AA, is gearing up to announce a significant decision – the curtailment of production at its Kwinana alumina refinery located in Western Australia, as reported by Bloomberg on Monday. Kwinana boasts a production capacity of 2.2 million metric tons of alumina, representing approximately 1.2% of the global output of this crucial raw material, as per data from the International Aluminum Institute. Currently, the plant is operating at around 80% of its maximum capacity. In 2023, Alcoa (AA) witnessed a decline in

January 8, 2024

Ron Finklestien

Time to Consider OneMain Holdings (OMF) Stock for Potential Growth? Time to Consider OneMain Holdings (OMF) Stock for Potential Growth?

With consumer lending stocks bouncing back within the financial sector, names like LendingTree, Ally Financial, Synchrony Financial, and OneMain Holdings are catching investors’ attention. After soaring near the $50-a-share range, OneMain’s stock is standing out among its industry peers. But is now a good time to consider buying OneMain’s stock for the potential of higher highs? Why OneMain’s Stock Stands Out OneMain has become a popular financial service holding company, offering personal loans, credit cards, optional credit insurance, and a financial wellness program. Despite the recent surge in OMF shares, they still trade at just 7.2X forward earnings, making their

January 8, 2024

Ron Finklestien

Alnylam Pharmaceuticals: Preliminary Full-Year ’23 Revenues Boast 39% Growth

Alnylam Pharmaceuticals ALNY reported a noteworthy 39% growth in full-year 2023 net product revenues, amounting to $1.24 billion. This surpassed Zacks Consensus Estimate’s projection of $1.83 billion. Flagship Products Fuel Growth In 2023, Alnylam saw strong performance from its four key products, namely Onpattro, Amvuttra, Givlaari, and Oxlumo. Onpattro and Amvuttra contributed over $913 million to the company’s net product revenues, marking a substantial 40% increase from the previous year. The sales of Givlaari and Oxlumo also rose to about $329 million, reflecting a 35% year-over-year improvement. The positive trajectory of these products has been instrumental in driving the company’s

January 8, 2024

Ron Finklestien

Tryp Therapeutics Pioneers Psilocybin Treatment Trials for IBS and Fibromyalgia Tryp Therapeutics Pioneers Psilocybin Treatment Trials for IBS and Fibromyalgia

Psychedelics biotech Tryp Therapeutics TRYPF is advancing its psilocybin-based portfolio through several recent milestones. Unveiling Upcoming Phase 1 Study for IV Psilocin In a groundbreaking development, the company has secured approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused psilocin, TRP-8803. This remarkable feat signifies a major step towards broadening the horizons of psychedelic medicine and fine-tuning the administration of IV psilocin for targeted therapeutic benefits. The study, slated to take place at the CMAX Phase 1 unit in Adelaide, Australia, will mark significant progress in assessing the safety and pharmacokinetics (PK)

January 8, 2024

Ron Finklestien

Palmer Square Capital BDC IPO Palmer Square Capital Business Development Company Aims to Raise $89.6M in IPO

4kodiak/iStock Unreleased via Getty Images Palmer Square Capital Business Development Company, an externally-managed firm, has submitted a prospectus to the Securities and Exchange Commission to initiate a public offering with the aim of raising $89.6 million. This momentous move was unveiled on Monday, eliciting interest and speculation among market analysts and enthusiasts. The corporation is presently awaiting regulatory consent to list its common stock under the trading symbol “PSBD” on the distinguished New York Stock Exchange, a pivotal step towards asserting itself in the aggressive arena of investment and finance. The envisioned offering entails the sale of 5.45 million shares